BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
65.48
+1.60 (2.50%)
At close: Jun 3, 2026, 4:00 PM EDT
65.48
0.00 (0.00%)
After-hours: Jun 3, 2026, 4:38 PM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
According to 24 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Strong Buy" and an average price target of $102.71. The average 1-year stock price forecast is 56.86% higher than the current stock price, while the lowest is $76 (+16.07%) and the highest is $157 (+139.77%).
Price Target: $102.71 (+56.86%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 15 | 16 | 16 | 15 | 16 |
| Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 22 | 23 | 23 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Initiates $104 | Buy | Initiates | $104 | +58.83% | Jun 3, 2026 |
| Citi | Citi | Hold Maintains $82 | Hold | Maintains | $82 | +25.23% | Jun 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $110 | Buy | Reiterates | $110 | +67.99% | May 28, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $94 → $98 | Buy | Maintains | $94 → $98 | +49.66% | May 27, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 27, 2026 |
Financial Forecast
Revenue This Year
963.18M
from 502.08M
Increased by 91.84%
Revenue Next Year
1.62B
from 963.18M
Increased by 68.51%
EPS This Year
-2.18
from -3.78
EPS Next Year
0.52
from -2.18
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.1B | ||
| Avg | 963.2M | ||
| Low | 844.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 120.2% | ||
| Avg | 91.8% | ||
| Low | 68.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.42 | ||
| Avg | -2.18 | ||
| Low | -3.20 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.